Atea Pharmaceuticals (NASDAQ: AVIR) announced that its hepatitis C drug combination bemnifosbuvir/ruzasvir (BEM/RZR) met both primary and secondary endpoints in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE